atai Life Sciences (NASDAQ: ATAI) (atai or Company), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, has announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of US$2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai.

Latham & Watkins advised atai Life Sciences in the offering, with a capital markets team led by New York partner Nathan Ajiashvili with associates Kaj Nielsen, Katie Byun, Adam Picker, and Skye Lee.